MERISTEM Therapeutics & SBH Sciences Announce Agreement for Joint Development of Animal-Free Recombinant Proteins
News Nov 29, 2007
MERISTEM Therapeutics and SBH Sciences have entered an agreement to co-develop recombinant proteins produced in genetically engineered tobacco for research and development and diagnostic applications.
The first proteins selected for development are human proteins from the growth factor and hormone families. Through the combined expertise of MERISTEM and SBH the companies will strive to provide a large variety of human proteins to Research and Development organizations.
Meristem's experience and know-how in plant-based stable expression of proteins combined with SBH's customized purification technology will ensure speed up of production and superior quality of proteins. Proteins expressed in Meristem's system are free of pathogens transmissible to humans.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019